Home » Newsletters » BioWorld Science

BioWorld Science

June 25, 2001

View Archived Issues

MorphoSys and ImmunoGen expand HuCAL collaboration

Selective VPAC2 receptor agonists hold potential for type 2 diabetes Rx

Very long-acting human insulin analogue presented by Novo Nordisk at ADA meeting

DPP-IV inhibitor improves metabolic control in type 2 diabetes

Safety of single and multiple doses of NBI-6024 demonstrated in type 1 diabetics

AT-1015, a 5-HT2 antagonist, improves nerve blood flow and sensory/motor deficits in diabetic rats

ADA news: preclinical findings support potential of FK-614 in type 2 diabetes

Initiation of phase III trials of TSE-424 triggers milestone payment from Wyeth to Ligand

NN-2211: preclinical and clinical data discussed at ADA scientific sessions

Corixa and Kirin form alliance for therapeutic monoclonal antibodies

Yasmin now available in the U.S.

Atovaquone nanosuspensions have excellent therapeutic efficacy in toxoplasmosis

AstraZeneca's Zomig approved in Japan for migraine

FDA issues nonapprovable letter to Wyeth-Ayerst for long-bone fracture therapy

DepoMed commences phase III trial of Metformin GR for type 2 diabetes

Nortran's antiarrhythmic agent shows oral bioavailability

Kosan Biosciences awarded SBIR grant for epothilone development

UroGenesys changes name to Agensys

NAVIGATOR trial to study nateglinide/valsartan for diabetes and cardiovascular disease prevention

Results for Vasogen's immune modulation therapy to be presented in September

Prous Science launches Integrity --the world's first integrated drug discovery portal

Heterocyclic compounds useful as medicines described by SCRAS

Methods of inhibiting ApoB secretion and/or inhibiting MTP patented by Pfizer

Japan Energy identifies protease inhibitors for HCV

Japanese labs collaborate on discovery of new TPO receptor ligands

Sphingomyelinase inhibitors discovered in natural sources at Kitasato Institute

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...